Precision medicine has helped identify several tumor molecular aberrations to be treated
with targeted therapies. These therapies showed substantial improvement in efficacy without …

Background Brain metastasis (BM) is common among cases of advanced non-small cell
lung cancer (NSCLC) and is the leading cause of death for these patients. Mesothelin …

Lung cancer is still the leading cause of cancer-related mortality. Over the past two decades,
the management of non-small cell lung cancer (NSCLC) has undergone a significant …

Chemotherapy and immunotherapy have shown no significant outcome for unresectable
pancreatic ductal adenocarcinoma (PDAC). Multi-drug combination therapy has become a …

Despite the initial benefit from tyrosine kinase inhibitors (TKI) targeting oncogenic ALK and
ROS1 gene fusions in non–small cell lung cancer, complete responses are rare and …

Objectives To compare the efficacy, safety and effects on quality of life of different ALK-
inhibitors for global and Asian patients with advanced ALK-positive non-small-cell lung …

Precision oncology has revolutionized the treatment of ALK-positive lung cancer with
targeted therapies. However, an unmet clinical need still to address is the treatment of …

The androgen receptor signaling inhibitor (ARSI) enzalutamide (Enz) has shown critical
efficacy in the treatment of advanced prostate cancer (PCa). However, the development of …

Extracellular vesicles (EVs) impact normal and pathological cellular signaling through
bidirectional trafficking. Exosomes, a subset of EVs possess biomolecules including …

Lung cancer is a leading cause of cancer-related morbidity and mortality worldwide.
Metastases in the brain are a common hallmark of advanced stages of the disease …